Aug. 4 at 11:01 AM
$TNYA a comparison nobody is making
if you want to understand what tenaya is actually becoming, look at
$ABCL.
abcellera. antibody discovery platform company. currently ~
$2.5-3B market cap. trades
$8-10 range. respected biotech name.
heres their story:
started as pure discovery services company. gave partners like lilly access to their antibody platform in exchange for research fees + milestones + royalties on any assets that succeeded. lilly COVID antibody deal made them famous.
then they expanded. regeneron. abbvie. novartis. gilead. 100+ partnered programs across the platform. royalty entitlements accumulating.
then they built proprietary pipeline USING their own platform. ABCL635, ABCL575, 20 internal programs. GMP manufacturing facility in vancouver. 2 molecules to clinic per year target.
result: platform + partnership + proprietary pipeline hybrid company. gets valued as a platform, not a single asset biotech.
$2.5-3B market cap even before proprietary pipeline delivers major data.
now look at TNYA:
three clinical programs owned in house (TN-201, TN-401, TN-301). proprietary iPSC cardiomyocyte discovery platform. alnylam collaboration signed march 2026,
$10M upfront,
$1.13B milestones across 15 targets. new corp dev CFO structuring more deals. asset light CDMO manufacturing model.
thats the ABCL playbook. same architecture. platform + partnerships + proprietary pipeline.
key parallels:
both monetize discovery platforms via partnerships + royalties. both have proprietary assets moving through clinic. both need market to value the PLATFORM layer separately from the lead assets. both benefit from milestone economics that compound over time. both got platform validation from a major pharma before proprietary assets delivered data.
key differences:
ABCL went capital HEAVY. built their own GMP facility.
TNYA is going capital LIGHT. exited union city lease, transferred to CDMO.
different strategic bet. asset light means faster to scale, lower fixed costs, better FCF per dollar. potentially SUPERIOR to the ABCL approach.
ABCL had
$500M+ cash from IPO. TNYA has
$80M with runway to H2 2027.
higher risk, higher reward. binary outcome forced sooner.
ABCL had 100+ partnerships when it hit
$2.5B. TNYA has 1 major partnership right now.
early innings. platform validation just beginning.
the math that matters:
ABCL current market cap: ~
$2.5-3B
TNYA current market cap:
$158M
thats a 15-20x gap. yes ABCL has more assets, more partnerships, more proven revenue. but they also had YEARS of platform recognition happen already.
TNYA today is where ABCL was in 2020-2021. one big partnership. proprietary pipeline moving to clinical proof. platform starting to get validated.
ABCL took 3-4 years to fully rerate from platform recognition to
$2.5-3B territory. TNYA is at year 0 of that journey.
the catalysts to watch (ABCL playbook):
first alnylam milestone hits (12-24 months) = platform revenue model validated
second major partnership signed = alnylam wasnt a one off
proprietary pipeline delivers clinical data (AHA nov 2026 = first big test) = market attention
TN-301 phase 1 progress = platform generates real assets across modalities
2-3 additional deals over next 24 months = full platform recognition
if TNYA follows ABCL trajectory over 3-5 years, market cap scales to
$1-3B. thats 6-20x from current levels.
the drawdown lesson:
ABCL had 60-70% drawdowns EVEN DURING their overall uptrend. platform companies zig-zag heavily. the 22% drawdown i’m sitting on right now would be a minor blip in ABCL history.
thats why the HODL discipline matters. platform recognition doesnt happen in a straight line. it happens through partnership announcements, milestone hits, proprietary data readouts, and eventually big pharma taking notice.
what makes TNYA the harder version:
ABCL never had compliance issues. never had delisting overhang. never had to prove platform value while sub
$1.
TNYA is doing the platform pivot under maximum pressure. if they pull it off, the rerate is MORE dramatic because the starting point is more depressed.
harder path. bigger payoff.
963k shares 0.9432 avg. HODL. this isnt a swing trade. its a 2-3 year platform recognition trade.
nfa
